{"id":54904,"date":"2023-03-16T13:03:43","date_gmt":"2023-03-16T12:03:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/"},"modified":"2023-03-16T13:03:43","modified_gmt":"2023-03-16T12:03:43","slug":"iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/","title":{"rendered":"iECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer"},"content":{"rendered":"
\n

\nDr. Cohn joins iECURE with a combined 30 years of academic medicine and industry expertise in rare genetic disorders with a focus on investigational biologics<\/i>\n<\/p>\n

PHILADELPHIA–(BUSINESS WIRE)–iECURE<\/b><\/a>, a gene editing company focused on mutation-agnostic in vivo<\/i> gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, today announced the appointment of Gabriel M. Cohn, M.D., MBA as Chief Medical Officer. Dr. Cohn will lead iECURE\u2019s clinical strategy for the company\u2019s pipeline of in vivo <\/i>gene editing therapies, including those designed to treat Ornithine Transcarbamylase (OTC) deficiency, citrullinemia type 1 (CTLN1), and phenylketonuria (PKU).\n<\/p>\n

<\/a><\/p>\n

\n\u201cGabe\u2019s experience in clinical development as a CMO will be crucial as we begin the process of global regulatory submissions and patient dosing. His diverse experiences in clinical development and gene therapy paired with a robust understanding of genetic disorders and leadership roles in the industry make him the ideal person to take the reins of our expanding clinical team,\u201d said Joseph Truitt, Chief Executive Officer of iECURE.\n<\/p>\n

\nDr. Cohn brings more than 30 years of experience in academic medicine as well as in the biotechnology industry, where he has contributed to the development of multiple therapeutics for the treatment of rare genetic disorders. Previously, he served as the Chief Medical Officer of Homology Medicines where he led the company\u2019s Phase 1\/2 gene therapy trial for PKU and supported two investigational new drug (IND) submissions to U.S. Food and Drug Administration (FDA) for the company\u2019s gene editing programs. Before joining Homology, he served as Vice President of Clinical Development at AVROBIO, leading clinical programs, protocol design, regulatory filings, FDA and Health Canada interactions and trial site identification and initiations. He has also served in executive leadership roles at OvaScience and Shire. Dr. Cohn is a Fellow of the American College of Genetics and Genomics (FACMG) and the American College of Obstetrics and Gynecology (ACOG), author of over 40 peer-reviewed publications, and served as the Chief of Clinical and Reproductive Genetics and Medical Director, Genetic Services at Baystate Medical Center and as Assistant Professor at Tufts University School of Medicine. He earned his M.D. from SUNY Health Science Center at Syracuse and MBA from the Isenberg School of Management at the University of Massachusetts Amherst. He completed a residency in Obstetrics & Gynecology at SUNY HSC at Syracuse and a fellowship in Medical Genetics at the National Institutes of Health.\n<\/p>\n

\n\u201cIt\u2019s a great privilege to join the iECURE team of incredibly successful and seasoned biopharma professionals who have a long track record of developing approved life-altering treatments, while also having an opportunity to collaborate with one of the world\u2019s premier centers of leadership and innovation in the field of genetic therapeutics,\u201d said Dr. Cohn. \u201cThey are at the forefront of advancing innovative approaches to gene editing that hold great promise for patients in need, and at this important time of growth and development, I look forward to working with the team and leading our clinical efforts in our goal to successfully treat rare genetic disorders including OTC, CTLN1, and PKU.\u201d\n<\/p>\n

\nAbout iECURE<\/b>\n<\/p>\n

\niECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo<\/i> gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team\u2019s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania\u2019s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP\u2019s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates. For more information, visit www.iecure.com<\/i><\/b><\/a> and follow on LinkedIn<\/i><\/b><\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:
\n
David Garrett
\n
dgarrett@iecure.com<\/i><\/b><\/a>\n<\/p>\n

\nMedia Contact:
\n
Danielle Cantey
\n
Canale Communications
\n
danielle.cantey@canalecomm.com<\/i><\/b><\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Dr. Cohn joins iECURE with a combined 30 years of academic medicine and industry expertise in rare genetic disorders with a focus on investigational biologics PHILADELPHIA–(BUSINESS WIRE)–iECURE, a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, today announced the appointment … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54904","6":"format-standard","7":"category-industry"},"yoast_head":"\niECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Dr. Cohn joins iECURE with a combined 30 years of academic medicine and industry expertise in rare genetic disorders with a focus on investigational biologics PHILADELPHIA–(BUSINESS WIRE)–iECURE, a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, today announced the appointment ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-16T12:03:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230316005259\/en\/1310882\/21\/iECURE_Logo_%282%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"iECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer\",\"datePublished\":\"2023-03-16T12:03:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\\\/\"},\"wordCount\":723,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230316005259\\\/en\\\/1310882\\\/21\\\/iECURE_Logo_%282%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\\\/\",\"name\":\"iECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230316005259\\\/en\\\/1310882\\\/21\\\/iECURE_Logo_%282%29.jpg\",\"datePublished\":\"2023-03-16T12:03:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230316005259\\\/en\\\/1310882\\\/21\\\/iECURE_Logo_%282%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230316005259\\\/en\\\/1310882\\\/21\\\/iECURE_Logo_%282%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"iECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/","og_locale":"en_US","og_type":"article","og_title":"iECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer - Pharma Trend","og_description":"Dr. Cohn joins iECURE with a combined 30 years of academic medicine and industry expertise in rare genetic disorders with a focus on investigational biologics PHILADELPHIA–(BUSINESS WIRE)–iECURE, a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, today announced the appointment ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-16T12:03:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230316005259\/en\/1310882\/21\/iECURE_Logo_%282%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"iECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer","datePublished":"2023-03-16T12:03:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/"},"wordCount":723,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230316005259\/en\/1310882\/21\/iECURE_Logo_%282%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/","url":"https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/","name":"iECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230316005259\/en\/1310882\/21\/iECURE_Logo_%282%29.jpg","datePublished":"2023-03-16T12:03:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230316005259\/en\/1310882\/21\/iECURE_Logo_%282%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230316005259\/en\/1310882\/21\/iECURE_Logo_%282%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"iECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54904","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54904"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54904\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54904"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54904"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54904"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}